ES2061591T3 - Administracion intranasal de polipeptidos en forma pulverizada. - Google Patents

Administracion intranasal de polipeptidos en forma pulverizada.

Info

Publication number
ES2061591T3
ES2061591T3 ES88117029T ES88117029T ES2061591T3 ES 2061591 T3 ES2061591 T3 ES 2061591T3 ES 88117029 T ES88117029 T ES 88117029T ES 88117029 T ES88117029 T ES 88117029T ES 2061591 T3 ES2061591 T3 ES 2061591T3
Authority
ES
Spain
Prior art keywords
polypeptides
intranasal administration
sprayed form
biologically active
active polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88117029T
Other languages
English (en)
Inventor
Brian H Vickery
Cherng-Chyi Fu
Eric J Benjamin
Lynda M Sanders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Application granted granted Critical
Publication of ES2061591T3 publication Critical patent/ES2061591T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPUESTOS FARMACEUTICOS DE POLIPEPTIDOS ACTIVOS BIOLOGICAMENTE EN FORMA PULVURULENTA APROPIADOS PARA ADMINISTRACION NASAL, COMPRENDEN UNA CANTIDAD TERAPEUTICA EFECTIVA DE POLIPEPTIDOS BIOLOGICAMENTE ACTIVOS Y UN POLISACARIDO SOLUBLE EN AGUA.
ES88117029T 1987-10-15 1988-10-13 Administracion intranasal de polipeptidos en forma pulverizada. Expired - Lifetime ES2061591T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10967887A 1987-10-15 1987-10-15

Publications (1)

Publication Number Publication Date
ES2061591T3 true ES2061591T3 (es) 1994-12-16

Family

ID=22328950

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88117029T Expired - Lifetime ES2061591T3 (es) 1987-10-15 1988-10-13 Administracion intranasal de polipeptidos en forma pulverizada.

Country Status (11)

Country Link
US (3) US6521597B1 (es)
EP (1) EP0312052B1 (es)
JP (1) JP2851627B2 (es)
KR (1) KR890006252A (es)
AT (1) ATE99543T1 (es)
AU (1) AU623609B2 (es)
CA (1) CA1336401C (es)
DE (1) DE3886880T2 (es)
ES (1) ES2061591T3 (es)
NZ (1) NZ226557A (es)
ZA (1) ZA887658B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
NZ226557A (en) * 1987-10-15 1990-07-26 Syntex Inc Pharmaceutical compositions for the intranasal administration of a biologically active polypeptide in powder form and process for their preparation
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
EP0565722A1 (en) * 1990-12-25 1993-10-20 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical preparation for pernasal administration
WO1993006862A1 (en) * 1991-10-11 1993-04-15 Toray Industries, Inc. Antibody composition
WO1993019771A1 (fr) * 1992-03-27 1993-10-14 Kirin Brewery Company, Limited Preparation administrable par voie nasale contenant un facteur de stimulation de colonies granulocytaires
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
CN1088580C (zh) 1994-12-22 2002-08-07 阿斯特拉公司 气溶胶药物制剂
EP0806945B1 (en) 1994-12-22 2003-04-23 AstraZeneca AB Therapeutic preparation for inhalation containing parathyro d hormone, pth
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
RO119862B1 (ro) * 1996-07-03 2005-05-30 Alza Corporation Formulare stabilă neapoasă şi procedeu pentru prepararea acesteia
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US7303768B2 (en) 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
WO2000004875A2 (en) * 1998-07-24 2000-02-03 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US7772220B2 (en) 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
WO2004028444A2 (en) * 1999-06-02 2004-04-08 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
US20080108086A1 (en) * 1999-06-02 2008-05-08 Cantor Thomas L Parathyroid hormone antagonists and uses thereof
JP2004500378A (ja) 2000-02-04 2004-01-08 ヨー、セオ、ホン 胆汁酸を含有する清浄水溶液製型の製造
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US20040152639A1 (en) * 2001-08-28 2004-08-05 Siler-Khodr Theresa M. Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
WO2003043574A2 (en) * 2001-11-19 2003-05-30 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
JP4124734B2 (ja) * 2001-11-26 2008-07-23 アスビオファーマ株式会社 経鼻吸収用医薬組成物
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
USRE45404E1 (en) 2003-03-27 2015-03-03 Shin Nippon Biomedical Laboratories, Ltd. Powder medicine applicator for nasal cavity
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US8778880B2 (en) * 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
US8673360B2 (en) 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
EP1789057B1 (en) 2004-08-30 2010-02-24 Seo Hong Yoo Neuroprotective effect of solubilized udca in focal ischemic model
US7148067B2 (en) * 2004-08-31 2006-12-12 The Board Of Trustees Of The University Of Illinois Thromboplastin reagents
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
WO2006044771A2 (en) 2004-10-15 2006-04-27 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
KR100834735B1 (ko) * 2004-11-15 2008-06-09 김두만 부신피질 기능 부전증 치료용 부신피질 자극 호르몬의비강 분무 제형
US20080260858A1 (en) * 2005-02-16 2008-10-23 The Board Of Trustees Of The University Of Illnois Universal Procoagulant
DE602006021290D1 (de) * 2005-03-04 2011-05-26 Univ Illinois Modulator von coagulationskaskaden und fibrinolytischen kaskaden
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
CA2620364A1 (en) 2005-08-26 2007-03-01 David C. Yeomans Methods for treatment of headaches by administration of oxytocin
US20080033038A1 (en) * 2006-07-07 2008-02-07 Shytle R D Compositions of polyphenols and methods of use
CN101668544B (zh) 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
EP2167069B1 (en) 2007-05-23 2011-10-26 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
WO2009023125A1 (en) * 2007-08-14 2009-02-19 The Board Of Trustees Of The Leland Stanford Junior University Neuronostatin and its uses
EP2188015A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of salusin beta alone or in combination with octreotide as a therapeutic agent
US8821861B2 (en) * 2007-10-05 2014-09-02 The Board Of Trustees Of The University Of Illinois Fibrin sealant
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
AU2009219204B2 (en) 2008-02-27 2013-01-17 Amcol International Corporation Methods of treating cardiovascular disorders associated with atherosclerosis
JP2012526726A (ja) * 2009-05-15 2012-11-01 株式会社新日本科学 薬物動態が改善された鼻腔内用薬学的組成物
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
HRP20231438T1 (hr) 2015-01-07 2024-06-07 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i načini uporabe
US20160361253A1 (en) * 2015-06-13 2016-12-15 Noveome Biotherapeutics, Inc. Novel Methods for Delivering Therapeutic Agents to the Eye via Nasal Passages
MX2018012351A (es) 2016-04-12 2019-02-07 Trigemina Inc Formulaciones de oxitocina que contienen magnesio y metodos de uso.
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CN110279656B (zh) * 2019-07-11 2021-11-09 温州医科大学 一种用于缓解鼻腔干燥的组合物及其制备方法和使用方法
TW202210072A (zh) 2020-05-26 2022-03-16 美商羅德科技公司 用於鼻內或吸入遞送之大麻素組合物及劑型

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
US4320118A (en) * 1980-12-22 1982-03-16 Syntex (U.S.A.) Inc. Deca-, undeca-, dodeca- and tridecapeptides with thymic activity
DE3372705D1 (en) * 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
JPS58189118A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd 経鼻投与製剤
US4581169A (en) * 1982-12-21 1986-04-08 Syntex (U.S.A.) Inc. Nona-peptide and deca-peptide analogs of LHRH, useful as LHRH antagonists
US4481190A (en) * 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4476116A (en) * 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4659693A (en) * 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4690916A (en) * 1984-11-13 1987-09-01 Syntex (U.S.A.) Inc. Nona and decapeptide analogs of LHRH useful as LHRH antagonists
JPS61144949A (ja) * 1984-12-18 1986-07-02 Nec Corp 着信側加入者端末の状態監視方式
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US4758584A (en) * 1987-02-05 1988-07-19 Ciba-Geigy Corporation Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups
US4801577A (en) * 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
NZ226557A (en) * 1987-10-15 1990-07-26 Syntex Inc Pharmaceutical compositions for the intranasal administration of a biologically active polypeptide in powder form and process for their preparation

Also Published As

Publication number Publication date
US6815424B2 (en) 2004-11-09
EP0312052A1 (en) 1989-04-19
KR890006252A (ko) 1989-06-12
ZA887658B (en) 1990-06-27
DE3886880T2 (de) 1994-07-14
JPH01132532A (ja) 1989-05-25
ATE99543T1 (de) 1994-01-15
US6521597B1 (en) 2003-02-18
US20030181387A1 (en) 2003-09-25
US20050089480A1 (en) 2005-04-28
CA1336401C (en) 1995-07-25
JP2851627B2 (ja) 1999-01-27
AU2375188A (en) 1989-06-01
EP0312052B1 (en) 1994-01-05
NZ226557A (en) 1990-07-26
AU623609B2 (en) 1992-05-21
DE3886880D1 (de) 1994-02-17

Similar Documents

Publication Publication Date Title
ES2061591T3 (es) Administracion intranasal de polipeptidos en forma pulverizada.
FI883785A7 (fi) Kapseli lääkeaineen farmaseuttisesti vaikuttavaa inhalointiainetta varten.
ATE286725T1 (de) Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
ATE234602T1 (de) Verabreichungsform zur abgabe von steigenden wirkstoffdosen
GEP20063773B (en) Steroid Sulphatase Inhibitors
FI870809L (fi) Menetelmä farmaseuttisessa valmisteessa käytettävän, veteen liukenevan, biologisesti aktiivisen, konjugoidun proteiinin valmistamiseksi
BR9303013A (pt) Composto,raloxifexo,cloridrato de raloxifeno e formulacao farmaceutica
FI972579L (fi) Emättimensisäisesti käytettävät lääkkeen vapauttamislaitteet 17 beta-estradioliprekursoreiden antamiseksi
ATE200025T1 (de) Flüssige arzneizubereitungen enthaltend schilddrüsenhormone
IS4509A (is) Innúðatæki, aðferð við að dreifa lyfjafræðilega virku efni og aðferð við inngjöf á skammti af lyfjafræðilega virku efni
ATE308317T1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
ES2183841T3 (es) Formas de dosificacion para administrar un farmasco en una formulacion lquidid.
FI932553A7 (fi) Uusia farmaseuttisia formulaatioita, jotka sisältävät farmakologisesti aktiivista ionisoitavaa ainetta, sekä menetelmä niiden valmistamiseksi
MY100721A (en) Therapeutic agent.
LV10196A (lv) Olbaltumviela biologiski aktivais hormons olbaltumvielas iegusanas panemiens farmaceitisks preparats
IT8667329A0 (it) Dispositivo osmotico comprendente mezzi per regolare la durata iniziale di erogazione di un agente medicinale da detto dispositivo
NO874960L (no) Flytende doseringsform for oral administrasjon av et farmasoeytisk aktivt stoff.
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
WO1999012527A3 (en) Dosage form comprising means for changing drug delivery shape
EP0160501A3 (en) Sustained release intranasal formulation and method of use thereof
ATE292453T1 (de) Antivirale arznei
FI891774L (fi) Menetelmä lääkeaineen anto- ja/tai annostelumuodon valmistamiseksi
DE3682229D1 (de) Zur stimulierung der traenensekretion verwendbare pharmazeutische praeparate.
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
FI970331A7 (fi) Lääkkeen antokoostumus virustenvastaisten aineiden nenään toteutettava a antoa varten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 312052

Country of ref document: ES